BURLINGTON, ON, Dec. 3 /CNW/ - The Jenex Corporation ("Jenex" or the
"Corporation") (TSX Venture Exchange: JEN, Frankfurt: JNX) announces a Private
Placement for gross proceeds of $2 million with a scheduled closing date to be
on or about December 14, 2007.
The Private Placement will consist of 20 million Units at a price of
$0.10 per Unit. Each Unit will consist of one common share and one half of one
share purchase warrant to purchase one whole share for $0.15 for a period of
Use of proceeds will be for marketing, advertising, education and
awareness programs for the Company's two products - interceptCS and Therapik.
The Private Placement will be subject to the customary four month hold
period from date of issue and TSX-V approval.
About The Jenex Corporation
Jenex has a non-invasive Medical Device that prevents cold sore
outbreaks. The interceptCS(TM) Cold Sore Prevention System is approved in
Canada and has received CE approval for European Union countries.
In addition to interceptCS, Jenex markets Therapik(R) for insect stings &
bites. Therapik immediately relieves the pain & itch caused by over 20,000
different insects. Therapik is approved in Canada and the United States and
Australia, as well as having CE Mark approval in the European Union countries.
Jenex's Thermal Therapy technology is patented in the U.S, Canada,
Australia, & Europe.
The TSX Venture Exchange Inc. has not reviewed and does not accept
responsibility for the accuracy or the contents of this press release.
Certain information included in this press release is forward-looking and
is subject to important risks and uncertainties. The results or events
predicted in these statements may differ materially from actual results
For further information:
For further information: Michael A. Jenkins, Tele: (905) 632-3830,
Facsimile: (905) 632-3774, Email: email@example.com, www.JenexCorp.com,